StockData
BioCryst Pharmaceuticals Inc logo

BioCryst Pharmaceuticals Inc (BCRX) stock

BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$7.22−0.10 (-1.37%)

Close on Nov 20, 2026Market cap $1.84BP/E –Yield –

BioCryst Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

BioCryst Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was $373.38M, up 2269.0% year over year. For fiscal 2025 it was $344.90M. The highest annual figure on record is $344.90M in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$344.90M–
FY2024Dec 31, 2024-$53.14M–
FY2023Dec 31, 2023-$97.31M–
FY2022Dec 31, 2022-$163.20M–
FY2021Dec 31, 2021-$144.54M–
FY2020Dec 31, 2020-$135.62M–
FY2019Dec 31, 2019-$89.93M–
FY2018Dec 31, 2018-$92.93M–
FY2017Dec 31, 2017-$41.47M–
FY2016Dec 31, 2016-$58.72M–
FY2015Dec 31, 2015-$18.24M–
FY2014Dec 31, 2014-$38.66M–
FY2013Dec 31, 2013-$26.56M–
FY2012Dec 31, 2012-$37.51M–
FY2011Dec 31, 2011-$32.31M–
FY2010Dec 31, 2010-$28.88M–
FY2009Dec 31, 2009-$16.82M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$104.13M+153.2%
Q1 FY2026Mar 31, 2026-$62.19M–
Q4 FY2025Dec 31, 2025$291.16M–
Q3 FY2025Sep 30, 2025$40.28M+392.1%
Q2 FY2025Jun 30, 2025$41.12M–
Q1 FY2025Mar 31, 2025-$27.66M–
Q4 FY2024Dec 31, 2024-$5.89M–
Q3 FY2024Sep 30, 2024$8.19M–
Q2 FY2024Jun 30, 2024-$1.52M–
Q1 FY2024Mar 31, 2024-$53.92M–
Q4 FY2023Dec 31, 2023-$9.47M–
Q3 FY2023Sep 30, 2023-$20.88M–
Q2 FY2023Jun 30, 2023-$19.28M–
Q1 FY2023Mar 31, 2023-$47.67M–
Q4 FY2022Dec 31, 2022-$24.38M–
Q3 FY2022Sep 30, 2022-$32.62M–
Q2 FY2022Jun 30, 2022-$28.00M–
Q1 FY2022Mar 31, 2022-$78.21M–
Q4 FY2021Dec 31, 2021-$33.57M–
Q3 FY2021Sep 30, 2021-$23.64M–
Q2 FY2021Jun 30, 2021-$26.22M–
Q1 FY2021Mar 31, 2021-$61.11M–
Q4 FY2020Dec 31, 2020-$42.69M–
Q3 FY2020Sep 30, 2020-$38.43M–
Q2 FY2020Jun 30, 2020-$31.11M–
Q1 FY2020Mar 31, 2020-$23.40M–
Q4 FY2019Dec 31, 2019-$10.53M–
Q3 FY2019Sep 30, 2019-$27.72M–
Q2 FY2019Jun 30, 2019-$24.59M–
Q1 FY2019Mar 31, 2019-$27.09M–
Q4 FY2018Dec 31, 2018-$24.09M–
Q3 FY2018Sep 30, 2018-$35.07M–
Q2 FY2018Jun 30, 2018-$14.08M–
Q1 FY2018Mar 31, 2018-$19.69M–
Q4 FY2017Dec 31, 2017-$10.63M–
Q3 FY2017Sep 30, 2017-$12.62M–
Q2 FY2017Jun 30, 2017-$9.69M–
Q1 FY2017Mar 31, 2017-$8.53M–
Q4 FY2016Dec 31, 2016-$5.85M–
Q3 FY2016Sep 30, 2016-$17.74M–

More BioCryst Pharmaceuticals figures

See a number that looks wrong?